Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?

Autores
Ridruejo, Ezequiel; Soza, Alejandro M. D.
Año de publicación
2019
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations suggest that only 25% of individuals with suspected HCV infection have been diagnosed, and only 4% received treatment.2 Recent availability in this region of directacting antivirals (DAAs), which are safer and more effective than the interferon-based therapies, may influence treatment paradigms at country levels.
Fil: Ridruejo, Ezequiel. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Soza, Alejandro M. D.. Pontificia Universidad Católica de Chile; Chile
Materia
HEPATITIS C
ERRADICATION
LATIN AMERICA
TREATMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/126656
Acceder
id CONICETDig_1098d731db8f293a21871de5ca0fa571
oai_identifier_str oai:ri.conicet.gov.ar:11336/126656
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?Ridruejo, EzequielSoza, Alejandro M. D.HEPATITIS CERRADICATIONLATIN AMERICATREATMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations suggest that only 25% of individuals with suspected HCV infection have been diagnosed, and only 4% received treatment.2 Recent availability in this region of directacting antivirals (DAAs), which are safer and more effective than the interferon-based therapies, may influence treatment paradigms at country levels.Fil: Ridruejo, Ezequiel. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Soza, Alejandro M. D.. Pontificia Universidad Católica de Chile; ChileJohn Wiley & Sons Inc2019-03-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/126656Ridruejo, Ezequiel; Soza, Alejandro M. D.; Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?; John Wiley & Sons Inc; Clinical Liver Disease; 13; 2; 4-3-2019; 43-452046-2484CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1002/cld.771info:eu-repo/semantics/altIdentifier/url/https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/cld.771info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-29T11:48:41Zoai:ri.conicet.gov.ar:11336/126656instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-29 11:48:42.185CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
title Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
spellingShingle Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
Ridruejo, Ezequiel
HEPATITIS C
ERRADICATION
LATIN AMERICA
TREATMENT
title_short Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
title_full Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
title_fullStr Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
title_full_unstemmed Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
title_sort Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?
dc.creator.none.fl_str_mv Ridruejo, Ezequiel
Soza, Alejandro M. D.
author Ridruejo, Ezequiel
author_facet Ridruejo, Ezequiel
Soza, Alejandro M. D.
author_role author
author2 Soza, Alejandro M. D.
author2_role author
dc.subject.none.fl_str_mv HEPATITIS C
ERRADICATION
LATIN AMERICA
TREATMENT
topic HEPATITIS C
ERRADICATION
LATIN AMERICA
TREATMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations suggest that only 25% of individuals with suspected HCV infection have been diagnosed, and only 4% received treatment.2 Recent availability in this region of directacting antivirals (DAAs), which are safer and more effective than the interferon-based therapies, may influence treatment paradigms at country levels.
Fil: Ridruejo, Ezequiel. Hospital Universitario Austral; Argentina. Latin American Liver Research, Educational and Awareness Network; Argentina. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Soza, Alejandro M. D.. Pontificia Universidad Católica de Chile; Chile
description Hepatitis C virus (HCV) infection is a global health concern with an estimated worldwide disease prevalence rate of 1%, meaning 71 million individuals are infected.1 In the United States, the estimated prevalence rate is 0.7%, or 7 million individuals.1 Specifically in Latin America, estimations suggest that only 25% of individuals with suspected HCV infection have been diagnosed, and only 4% received treatment.2 Recent availability in this region of directacting antivirals (DAAs), which are safer and more effective than the interferon-based therapies, may influence treatment paradigms at country levels.
publishDate 2019
dc.date.none.fl_str_mv 2019-03-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/126656
Ridruejo, Ezequiel; Soza, Alejandro M. D.; Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?; John Wiley & Sons Inc; Clinical Liver Disease; 13; 2; 4-3-2019; 43-45
2046-2484
CONICET Digital
CONICET
url http://hdl.handle.net/11336/126656
identifier_str_mv Ridruejo, Ezequiel; Soza, Alejandro M. D.; Which Strategies Should Be Implemented in Latin America to Eradicate Hepatitis C Virus by 2030?; John Wiley & Sons Inc; Clinical Liver Disease; 13; 2; 4-3-2019; 43-45
2046-2484
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1002/cld.771
info:eu-repo/semantics/altIdentifier/url/https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/cld.771
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv John Wiley & Sons Inc
publisher.none.fl_str_mv John Wiley & Sons Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1847426508304416768
score 13.10058

Publicaciones similares